BACKGROUND: Skeletal complications during or after treatment of acute lymphoblastic leukemia (ALL) have been frequently reported and can cause substantial morbidity, yet their incidence is not well established. The present study assessed the incidence of fractures, osteonecrosis (ON), and bone pain during ALL treatment and compared the fracture incidence with age- and sex-specific reference data from the UK General Practice Research Database (GPRD). PROCEDURE: Medical records of 122 ALL patients diagnosed at our institution from 1992 to 2004 were reviewed for information on fractures, ON, bone pain, and their anatomical location, risk group, phase of antileukemic therapy, and time since diagnosis. Evaluation of skeletal complications was followed up until July 2005 or the patient's death. Thirteen children were excluded as they were transferred to other institutions shortly after diagnosis. RESULTS: Skeletal complications occurred at a 5-year incidence of 32.7%. The 5-year incidence of fractures, ON, and isolated bone pain was 13.5%, 12.1%, and 12.3%, respectively. The relative rate of fractures adjusted for age and sex was 2.03 (95% confidence interval 1.15-3.57) compared to the GPRD, with greatest rates in children <5 years. Thirty ON occurred in 10 patients with a 15 times greater incidence in children >10 years than in those <5 years. Nearly all skeletal complications occurred during maintenance therapy at a median of 14.92 months (range 0.0-53.8) after diagnosis and in weight-bearing bones. CONCLUSIONS: The doubled fracture rate and the high incidence of skeletal complications during the first years after diagnosis suggest the developing skeleton is very vulnerable in this period. Adolescents develop more ON whereas younger children may be more prone to fractures. Serious "immediate effects" of chemotherapy on bone appear of great concern and should entail preventative studies in this group of patients. (c) 2006 Wiley-Liss, Inc.
BACKGROUND: Skeletal complications during or after treatment of acute lymphoblastic leukemia (ALL) have been frequently reported and can cause substantial morbidity, yet their incidence is not well established. The present study assessed the incidence of fractures, osteonecrosis (ON), and bone pain during ALL treatment and compared the fracture incidence with age- and sex-specific reference data from the UK General Practice Research Database (GPRD). PROCEDURE: Medical records of 122 ALL patients diagnosed at our institution from 1992 to 2004 were reviewed for information on fractures, ON, bone pain, and their anatomical location, risk group, phase of antileukemic therapy, and time since diagnosis. Evaluation of skeletal complications was followed up until July 2005 or the patient's death. Thirteen children were excluded as they were transferred to other institutions shortly after diagnosis. RESULTS: Skeletal complications occurred at a 5-year incidence of 32.7%. The 5-year incidence of fractures, ON, and isolated bone pain was 13.5%, 12.1%, and 12.3%, respectively. The relative rate of fractures adjusted for age and sex was 2.03 (95% confidence interval 1.15-3.57) compared to the GPRD, with greatest rates in children <5 years. Thirty ON occurred in 10 patients with a 15 times greater incidence in children >10 years than in those <5 years. Nearly all skeletal complications occurred during maintenance therapy at a median of 14.92 months (range 0.0-53.8) after diagnosis and in weight-bearing bones. CONCLUSIONS: The doubled fracture rate and the high incidence of skeletal complications during the first years after diagnosis suggest the developing skeleton is very vulnerable in this period. Adolescents develop more ON whereas younger children may be more prone to fractures. Serious "immediate effects" of chemotherapy on bone appear of great concern and should entail preventative studies in this group of patients. (c) 2006 Wiley-Liss, Inc.
Authors: Elizabeth A Cummings; Jinhui Ma; Conrad V Fernandez; Jacqueline Halton; Nathalie Alos; Paivi M Miettunen; Jacob L Jaremko; Josephine Ho; Nazih Shenouda; Mary Ann Matzinger; Brian Lentle; David Stephure; Robert Stein; Ann Marie Sbrocchi; Celia Rodd; Bianca Lang; Sara Israels; Ronald M Grant; Robert Couch; Ronald Barr; John Hay; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Nathalie Alos; Ronald M Grant; Timothy Ramsay; Jacqueline Halton; Elizabeth A Cummings; Paivi M Miettunen; Sharon Abish; Stephanie Atkinson; Ronald Barr; David A Cabral; Elizabeth Cairney; Robert Couch; David B Dix; Conrad V Fernandez; John Hay; Sara Israels; Caroline Laverdière; Brian Lentle; Victor Lewis; MaryAnn Matzinger; Celia Rodd; Nazih Shenouda; Robert Stein; David Stephure; Shayne Taback; Beverly Wilson; Kathryn Williams; Frank Rauch; Kerry Siminoski; Leanne M Ward Journal: J Clin Oncol Date: 2012-06-25 Impact factor: 44.544
Authors: Jinhui Ma; Kerry Siminoski; Nathalie Alos; Jacqueline Halton; Josephine Ho; Brian Lentle; MaryAnn Matzinger; Nazih Shenouda; Stephanie Atkinson; Ronald Barr; David A Cabral; Robert Couch; Elizabeth A Cummings; Conrad V Fernandez; Ronald M Grant; Celia Rodd; Anne Marie Sbrocchi; Maya Scharke; Frank Rauch; Leanne M Ward Journal: J Clin Endocrinol Metab Date: 2014-12-11 Impact factor: 5.958
Authors: Maria Luisa Bianchi; Sanford Baim; Nick J Bishop; Catherine M Gordon; Didier B Hans; Craig B Langman; Mary B Leonard; Heidi J Kalkwarf Journal: Pediatr Nephrol Date: 2009-07-15 Impact factor: 3.714